Dephosphorylated MET was found to promote autophagy in liver cancer and gastric cancer, suggesting that a combination of kinase activity-targeted drugs and autophagy inhibitors is a potential treatment strategy [31, 32]. The gene discussed is MET; the disease is liver cancer.